Ignite Creation Date:
2024-05-05 @ 11:07 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002129
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Phase I Study of Three Doses of OPC-8212 Vesnarinone in HIV-Infected Persons With CD4 Cell Number 300 Cellsmm3
Sponsor:
Otsuka America Pharmaceutical
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Phase I Study of Three Doses of OPC-8212 Vesnarinone in HIV-Infected Persons With CD4 Cell Number 300 Cellsmm3
Status:
COMPLETED
Status Verified Date:
1996-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To examine the safety and tolerance of three doses of oral vesnarinone in HIV-infected patients with CD4 count 300 cellsmm3
Detailed Description:
Twelve patients per dose level receive vesnarinone at 1 of 3 doses for 12 weeks At least six patients at a given dose level must have completed 2 weeks of treatment before dose is escalated in subsequent patients
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 22-93-251 | None | None | None |